[Progress in the treatment of degenerative diseases of the nervous system. Selected problems].
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy*; D008094:Lithium / Q000627:therapeutic use; D009388:Neostigmine / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010396:Penicillamine / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D012642:Selegiline / Q000627:therapeutic use; D013747:Tetrabenazine / Q000627:therapeutic use; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use
D000978:Antiparkinson Agents; D010793:Phthalazines; D012642:Selegiline; D009388:Neostigmine; C011329:phthalazinol; D008094:Lithium; D010396:Penicillamine; D013976:Tiapamil Hydrochloride; D013747:Tetrabenazine
Postepy w leczeniu chorób zwyrodnieniowych układu nerwowego.